Catalyst Pharmaceuticals (CPRX) Announces Upcoming CEO Retirement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
July 25, 2023 8:03 AM EDTMr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement
Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search
CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that Patrick J. McEnany, Catalysts Co-Founder, Chairman, and Chief Executive Officer ("CEO") has informed the Board of Directors ("Board") of his intention to retire from his position as CEO by the end of 2023. Mr. McEnany... More
